Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2

Cancer Research

Volumn 74, Issue 4, 2014, Pages 1067-1078

  Lopez Rivera, Esther ^a   Jayaraman, Padmini ^a   Parikh, Falguni ^a   Davies, Michael A ^d   Ekmekcioglu, Suhendan ^d   Izadmehr, Sudeh ^c   Milton, Denái R ^d   Chipuk, Jerry E ^a,b   Grimm, Elizabeth A ^d   Estrada, Yeriel ^a   Aguirre Ghiso, Julio ^a   Sikora, Andrew G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Tisch Cancer Institute   (United States)

^c University of Texas MD Anderson Cancer Center ^*  (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CELL PROLIFERATION; CHICK EMBRYO; GENE KNOCKDOWN TECHNIQUES; HUMANS; MELANOMA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITROSATION; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84894273991     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0588     Document Type: Article

References (44)

1. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology 2009;23:488-96.
2. Wang GY, Ji B, Wang X, Gu JH. Anti-cancer effect of iNOS inhibitor and its correlation with angiogenesis in gastric cancer. World J Gas-troenterol 2005;11:3830-3.
3. Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, Soini Y. Inducible nitric oxide synthase expression, apoptosis, and angiogen-esis in in situ and invasive breast carcinomas. Clin Cancer Res 2000;6:2408-16.
4. Pukkila MJ, Kellokoski JK, Virtaniemi JA, Kumpulainen EJ, Johansson RT, Halonen PM, et al. Inducible nitric oxide synthase expression in pharyngeal squamous cell carcinoma: relation to p53 expression, clinicopathological data, and survival. Laryngoscope 2002;112: 1084-8.
5. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000;6:4768-75.
6. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 2006;119:861-6.
7. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-34.
8. Azad N, Vallyathan V, Wang L, Tantishaiyakul V, Stehlik C, Leonard SS, et al. S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apo-ptosis. J Biol Chem 2006;281:34124-34.
9. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 1995;31A:1898-902.
10. Mannick JB, Schonhoff CM. Analysis of protein S-nitrosylation. Curr Protoc Protein Sci 2006; Chapter 14:Unit 14.6.
11. Ekmekcioglu S, Tang CH, Grimm EA. NO news is not necessarily good news in cancer. Curr Cancer Drug Targets 2005;5:103-15.
12. Wink DA, Ridnour LA, Hussain SP, Harris CC. The reemergence of nitric oxide and cancer. Nitric Oxide 2008;19:65-7.
13. Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 2005;10:2986-3001.
14. Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin-and farnesylation-dependent manner. J Biol Chem 2003; 278:32493-6.
15. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003;13:1259-68.
16. Zhang L, Cardinal JS, Bahar R, Evankovich J, Huang H, Nace G, et al. Interferon regulatory factor-1 regulates the autophagic response in LPS-stimulated macrophages through nitric oxide. Mol Med 2012;18: 201-8.
17. Doronzo G, Viretto M, Russo I, Mattiello L, Di Martino L, Cavalot F, et al. Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: influence of insulin resistance and oxidative stress. Atherosclerosis 2011;216:44-53.
18. Zhang J, Hua ZC. Targeted gene silencing by small interfering RNA-based knock-down technology. Curr Pharm Biotechnol 2004; 5:1-7.
19. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38 (SAPK). Cancer Res 2003;63:1684-95.
20. Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997;137:767-77.
21. Navarro-Lerida I, Martinez-Moreno M, Ventoso I, Alvarez-Barrientos A, Rodriguez-Crespo I. Binding of CAP70 to inducible nitric oxide synthase and implications for the vectorial release of nitric oxide in polarized cells. Mol Biol Cell 2007;18:2768-77.
22. Alhassen F, Kudrolli H, Singh B, Kim S, Seo Y, Gould RG, et al. Depth-of-interaction compensation using a focused-cut scintillator for a pinhole gamma camera. IEEE Trans Nucl Sci 2011;58:634-8.
23. Li Y, Inoki K, Guan KL. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol 2004; 24:7965-75.
24. Jaffrey SR, Snyder SH. The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE 2001;2001:pl1.
25. Wouters A, Pauwels B, Lambrechts HA, Pattyn GG, Ides J, Baay M, et al. Countingclonogenic assaysfrom normoxic andanoxicirradiation experiments manually or by using densitometric software. Phys Med Biol 2010;55:N167-78.
26. Robertson FM, Long BW, Tober KL, Ross MS, Oberyszyn TM. Gene expression and cellular sources of inducible nitric oxide synthase during tumor promotion. Carcinogenesis 1996;17:2053-9.
27. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, et al. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 2010;16:1834-44.
28. Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, et al. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 2012;188:5365-76.
29. Selby PJ, Courtenay VD, McElwain TJ, Peckham MJ, Steel GG. Colony growth and clonogenic cell survival in human melanoma xenografts treated with chemotherapy. Br J Cancer 1980;42:438-47.
30. Zaffaroni N, De Marco C, Villa R, Riboldi S, Daidone MG, Double JA. Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. Eur J Cancer 2001;37:1953-62.
31. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
32. Mainwaring PN, Ellis PA, Detre S, Smith IE, Dowsett M. Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer. J Clin Pathol 1998;51:34-7.
33. Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. Invest Ophthalmol Vis Sci 2010;51:421-9.
34. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012;485:55-61.
35. Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res 2007; 67:289-99.
36. Forrester MT, Foster MW, Benhar M, Stamler JS. Detection of protein S-nitrosylation with the biotin-switch technique. Free Radic Biol Med 2009;46:119-26.
37. Yasukawa T, Tokunaga E, Ota H, Sugita H, Martyn JA, Kaneki M. S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J Biol Chem 2005;280:7511-8.
38. Kwak YD, Ma T, Diao S, Zhang X, Chen Y, Hsu J, et al. NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. Mol Neurodegener 2010;5:49.
39. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
40. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-9.
41. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-72.
42. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7.
43. Singh S, Gupta AK. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol 2011;67: 1211-24.
44. Kong G, Kim EK, Kim WS, Lee YW, Lee JK, Paik SW, et al. Inducible nitric oxide synthase (iNOS) immunoreactivity and its relationship to cell proliferation, apoptosis, angiogenesis, clinicopathologic characteristics, and patient survival in pancreatic cancer. Int J Pancreatol 2001;29:133-40.